Clinical Trial Navigation to Increase Participation and Diversity in Cancer Clinical Trials

Description

This clinical trial evaluates a clinical trial navigation intervention to help increase participation and diversity in cancer clinical trials. Cancer clinical trials are an important part of the development of treatments, and improved patient care and outcomes. Despite this, only a small number of cancer patients participate in clinical trials. There are many different items that contribute to low clinical trial participation, including health-related social needs (HRSN) and financial burden. Guiding participation toward understanding, inclusion, diversity, and equity for cancer clinical trials (GUIDE), is a program that uses a trained clinical trial navigator, or "Guide", to work with identified potential cancer clinical trial patients to help them recognize and remove HRSN and financial barriers preventing clinical trial participation. A clinical trial navigation intervention, like GUIDE, may help increase participation and diversity in cancer clinical trials.

Conditions

Breast Carcinoma, Digestive System Carcinoma, Genitourinary System Carcinoma

Talk to us

Study Overview

On this page

Study Details

Study overview

This clinical trial evaluates a clinical trial navigation intervention to help increase participation and diversity in cancer clinical trials. Cancer clinical trials are an important part of the development of treatments, and improved patient care and outcomes. Despite this, only a small number of cancer patients participate in clinical trials. There are many different items that contribute to low clinical trial participation, including health-related social needs (HRSN) and financial burden. Guiding participation toward understanding, inclusion, diversity, and equity for cancer clinical trials (GUIDE), is a program that uses a trained clinical trial navigator, or "Guide", to work with identified potential cancer clinical trial patients to help them recognize and remove HRSN and financial barriers preventing clinical trial participation. A clinical trial navigation intervention, like GUIDE, may help increase participation and diversity in cancer clinical trials.

Guiding Participation Toward Understanding, Inclusion, Diversity, and Equity for Cancer Clinical Trials (GUIDE) Pilot Trial

Clinical Trial Navigation to Increase Participation and Diversity in Cancer Clinical Trials

Condition
Breast Carcinoma
Intervention / Treatment

-

Contacts and Locations

Seattle

Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States, 98109

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Patients ≥ 18 years of age
  • * Identified as potentially eligible for an open clinical trial by clinical trial pre-screening (operating in breast, gastrointestinal \[GI\], and genitourinary \[GU\] clinics)
  • * Have ≥ 1 health related social need, defined by
  • * Food insecurity, housing instability, transportation challenges, or financial instability documented in the Supportive Cancer Care Questionnaire in Epic Electronic Medical Record (EPIC), OR
  • * Concerns about insurance, cost of trial, additional trial visits, travel, transportation, childcare, OR unable to take time off work documented by clinical trial pre-screening (CTPS), OR
  • * Medicaid insurance documented in EPIC
  • * Able to speak English
  • * Unable to speak English
  • * Children, adolescents, and teens under the age of 18 years
  • * Patients participating on clinical trials providing financial navigation, such as clinicaltrials.gov identifier (CT ID): NCT04960787
  • * Patients refusing to sign Health Insurance Portability and Accountability Act (HIPAA) authorization

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Fred Hutchinson Cancer Center,

Jason Mendoza, MD, MPH, PRINCIPAL_INVESTIGATOR, Fred Hutch/University of Washington Cancer Consortium

Study Record Dates

2025-09-01